<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00419081</url>
  </required_header>
  <id_info>
    <org_study_id>BCX1777-Tio-05-202</org_study_id>
    <nct_id>NCT00419081</nct_id>
  </id_info>
  <brief_title>Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens</brief_title>
  <official_title>A Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Forodesine Hydrochloride is effective in
      treating patients with relapsed/refractory precursor T-Lymphoblastic Leukemia/Lymphoma who
      have failed two or more prior treatment regimens.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Issues with Manufacturing
  </why_stopped>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the rate of complete remission for T lymphoblastic leukemia/lymphoma relapsed or refractory patients. The complete remission rate will be evaluated over the three-month Initial Treatment Period.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the rate of CR achieved based on prior HSCT status</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess safety and tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess survival end points</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the maintenance and duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the proportion of patients able to proceed to HSCT</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effects of this forodesine regimen on plasma levels of dGuo</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the effects of this forodesine regimen on clinical end points</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore potential predictive biomarkers</measure>
  </secondary_outcome>
  <enrollment>100</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Forodesine Hydrochloride Sterile Solution, 5 mg/mL</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Forodesine Hydrochloride Capsules (100 mg)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with an unequivocal histologic diagnosis of precursor T-lymphoblastic
             leukemia/lymphoma (World Health Organization [WHO] classification).

          -  Failure to have responded to or relapsed after two or more treatment regimens for
             their disease, one of which could be HSCT.

          -  Performance status of 2 by Eastern Cooperative Oncology Group (ECOG) criteria (see
             Appendix A).

          -  Eighteen years of age and older.

          -  Life expectancy of at least three months.

          -  Adequate liver function (aspartate aminotransferase [AST] and/or alanine
             aminotransferase [ALT] â‰¤3 times upper limit of normal), unless related to the
             underlying leukemia.

          -  Negative serum or urine pregnancy test within two to seven days prior to the start of
             study treatment in females of childbearing potential.

          -  Females of childbearing potential and males must be willing and able to use an
             adequate method of contraception to avoid pregnancy for the duration of the study in
             such a manner that the risk of pregnancy is minimized. Acceptable contraceptives
             include intra-uterine devices (IUDs), hormonal contraceptives (oral, depot, patch, or
             injectable), and double-barrier methods such as condoms or diaphragms with spermicidal
             gel or foam.

          -  Signed informed consent form (ICF) prior to start of any study-specific procedures.

          -  Willing and able to provide authorization for the use and disclosure of personal
             health information in accordance with Health Insurance Portability and Accountability
             Act (HIPAA) policy (U.S. patients only).

        Exclusion Criteria:

          -  Patients with known human immunodeficiency virus (HIV) infection or human T
             lymphotrophic virus 1 (HTLV-1).

          -  Patients with active hepatitis B or C infection.

          -  Patients with clinical evidence of active central nervous system (CNS) leukemia.

          -  Active serious infection not controlled by oral or intravenous antibiotics.

          -  Patients with a calculated creatinine clearance of &lt;50 mL/min.

          -  Prior treatment with any investigational antileukemic or chemotherapy agent within
             seven days prior to study entry or lack of full recovery from side effects due to
             prior therapy, independent of when that therapy was given.

          -  Rapidly progressive disease with compromised organ function judged to be life
             threatening by the Investigator.

          -  Concurrent treatment with other antileukemia agents (CNS prophylaxis [e.g.,
             intrathecal methotrexate, cytarabine, or hydrocortisone] and corticosteroid use will
             not be excluded, but must first be approved by the Medical Monitor) (see Sections
             9.2.1 and 9.2.2).

          -  Pregnant and/or lactating female.

          -  Patients who cannot swallow or who have chronic gastrointestinal disease or conditions
             that may hamper compliance and/or absorption of the product.

          -  Hypersensitive or intolerant to any component of the study drug formulations.

          -  Patients who have received prior forodesine treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Auro del Giglio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina do ABC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Belinda Pinto Simoes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital das Clinicas de Faculdade de Medicina de Ribeirao Preto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Sergio Chiattone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Irmandade da Santa Casa de Misercordia de Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmino Antonio de Souza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clinicias da UICAMP - Centro de Hematologia e Hemoterapia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Barqueti Jendiroba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Goiano de Oncologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ernesto de Meis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INCA - Instituto Nacional de Cancer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Antonio Sellos Ribeiro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Estadual de Hematologia Artur de Siqueira Cavalcanti - HEMORIO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ines Guterres, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Nossa Senhora de Conceicao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johnny Francisco Cordeiro Camargo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Erasto Gaertner - Liga Paranaense de Combate ao Cancer - CEPEP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Salvador Rodrigues Oliveira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Santa Marcelina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucia Mariano da Rocha Silla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clinicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mair Pedro de Souza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacao Hospital Amaral Carvalho</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Aparecida Zanichelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Brigadeiro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Lucia de Martino Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Oncologia Pediatrica - GRAACC Grupo de Apoio as Adolescente e a Crianca com Cancer - UNIFESP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo Pasquini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clinicas da Universidade Federal do Parana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicholas Novitzky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Haematology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vernon Louw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Free State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Farhad Ravandi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Seiter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College, Division of Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Turturro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Louisana State University Health Sciences Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Isola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wendy Stock, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Gonzalez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liberty Hematology and Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Foran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ellen Ritchie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonard Heffner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Emory Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Madan Jagasia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katarzyna Jamieson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary Schiller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anjali Advani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kellie Sprague, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tanya Trippett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meir Wetzler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Gaiger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Werner Linkersch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Heamtology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Nachbaur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Heamatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Agnes Buzin, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Stephane de Botton, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Jacques Delaunnay, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Herve Dombret, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service Clinique des Maladies du Sang</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francoise Huguet-Rigal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'Hematologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Ifrah, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Arnaud Pigneux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU du Hart Leveque</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Quesnel, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Houmedaly Reman, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Xavier Thomas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maladies du Sang</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Vey, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Francis Witz, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Genadi Iosava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Heamatology &amp; Transfusiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mamia Zodelava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heamatology and Transfusiology Dept</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reinhard Andreesen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitat Regensburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter Aulitzky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Innere Abt. II</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrich Duehrsen, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Gerhard Ehninger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Carl Gustav Carus der Technischen Universitat</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnold Ganser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ABT Hamatologie und Onkologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. Haas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitatsklinik Dusseldorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dieter Hoelzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiterin der Studienzentrale</affiliation>
  </overall_official>
  <overall_official>
    <last_name>W-D Ludwig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite Universitatsmedizin Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deiter Niederwieser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abt. Haematologie / Onkologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Pfreunschuh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Klinik I</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mathias Schmid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Innere Medizin III, Hamatologie und Onkologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Schmitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamatologsiche Abteilung</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Staib, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Med. Klinik I / Hamatolgie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthias Stelljes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Innere Medizin A</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele Baccarani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istitutp di Ematologia ed Oncologia Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renato Bassan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dipartimento di Oncoloia ed Ematico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Bosi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aziendo Osperdaliero Universitaria Careggi Oncologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felicetto Ferrara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Antonio Cardarelli</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Foa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cattedra di Ematologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugenio Gallo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Divisione di Ematologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincenzo Liso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UO Universita degi Studi Policinico Ematologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salvatore Mirto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Osperdaliera Vincenzo Cervello Divisione</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrica Morra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complessa di Ematologia and Dir Departmento</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrico Pogliani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ematologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bob Lowenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eramus University Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerzy Holowiecki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinika Hematologii I</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wieslaw Jedrzejczak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinika Hematologii i Onkologii</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kazimierz Kuliczkowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Heamatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tadeusz Robak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinika Hematologii Akademii Meduycznej Wojewodzki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aleksander Skotnicki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Katedra i Klinika Hematologii Collegium Medicum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K. Abdulkadyrov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Hematology Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anatoli Golenkov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Clinical Heam and Immunotherapy Dept.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S. Moiseev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty Therapy Dept</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valerie Savchenko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dir. Research Institute for BMT and Molecular Hematology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Ribera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Insitut CatalÃ  d'Oncologia-Hospital Universitari Germans Trias i Pujol</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisana State University Health Sciences Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College Division of Oncology</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liberty Hematology and Oncology</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2007</study_first_submitted>
  <study_first_submitted_qc>January 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2007</study_first_posted>
  <disposition_first_submitted>January 18, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>January 18, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 23, 2012</disposition_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leukemia</keyword>
  <keyword>lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

